Physician profile
Jonathan White
NPI 1366163297
$717.51
in general payments reported to CMS, 2019-2025
8 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $51.56 · 2023: $187 · 2024: $155 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $489 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $489.46 |
| Education | $176.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $287.75 | 2022-2025 | Invega Sustenna, Invega Trinza, Invega |
| Teva Pharmaceuticals USA, INC. | $131.91 | 2023-2025 | Uzedy |
| Alkermes, INC. | $94.48 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $83.28 | 2022-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $58.59 | 2022-2025 | Ingrezza |
| Braeburn INC. | $26.66 | 2025 | Brixadi |
| Abbvie INC. | $19.75 | 2024 | |
| Lundbeck LLC | $15.09 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.